Department of Biosciences & Bioengineering, Wadhwani Research Centre in Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India.
Nanomedicine. 2012 Jul;8(5):665-72. doi: 10.1016/j.nano.2011.08.004. Epub 2011 Sep 1.
Acute lung injury causes inactivation of pulmonary surfactant due to leakage of albumin and other markers. Current surfactants are ineffective in this condition and are instilled intratracheally. Nanovesicles of 300 ± 50 nm composed of nonlamellar phospholipids were developed as pulmonary surfactant aerosols for therapy in acid-induced lung injury. A combination of dipalmitoyl phosphatidylcholine and dioleoyl phosphatidylethanolamine was used. The size and composition of the nanovesicles were optimized for an improved airway patency in the presence of albumin and serum. In an acid-induced lung injury model in mice, on treatment with nanovesicle aerosols at a dose of 200 mg/kg, the alveolar protein leakage decreased from 8.62 ± 0.97 μg/mL to 1.94 ± 0.74 μg/mL, whereas the airway patency of the bronchoalveolar lavage fluid increased from 0.6 ± 0.0% to 91.7 ± 1.05%. Nanovesicle aerosols of nonlamellar lipids improved the resistance of pulmonary surfactants to inhibition and were promising as a noninvasive aerosol therapy in acute lung injury.
In acute lung injury, intrinsic surfactants are inactivated via albumin leakage and other mechanisms. Currently existing intratracheal surfactants are ineffective in this condition. The authors demonstrate that novel nanovesicle aerosols of nonlamellar lipids improved the resistance of pulmonary surfactants to inhibition and are promising as a noninvasive aerosol therapy in acute lung injury.
急性肺损伤会导致肺表面活性物质因白蛋白和其他标志物的渗漏而失活。目前的表面活性剂在这种情况下无效，并且是通过气管内滴注的方式给药。研究人员开发了由非层状磷脂组成的 300±50nm 的纳米囊泡作为肺表面活性物质气雾剂，用于治疗酸诱导的肺损伤。使用了二棕榈酰磷脂酰胆碱和二油酰磷脂酰乙醇胺的组合。为了在存在白蛋白和血清的情况下改善气道通畅性，对纳米囊泡的大小和组成进行了优化。在小鼠酸诱导的肺损伤模型中，用 200mg/kg 的纳米囊泡气雾剂治疗后，肺泡蛋白泄漏从 8.62±0.97μg/ml 降低到 1.94±0.74μg/ml，而支气管肺泡灌洗液的气道通畅性从 0.6±0.0%增加到 91.7±1.05%。非层状脂质的纳米囊泡提高了肺表面活性剂的抗抑制能力，有望成为急性肺损伤的非侵入性气雾剂治疗方法。
在急性肺损伤中，内在的表面活性剂通过白蛋白渗漏和其他机制失活。目前存在的气管内表面活性剂在这种情况下无效。作者证明，新型非层状脂质纳米囊泡提高了肺表面活性剂的抗抑制能力，有望成为急性肺损伤的非侵入性气雾剂治疗方法。
